News

IMUNON Announces IMNN-001 Abstract Accepted for Oral Presentation at 2025 ASCO Annual Meeting
Highly promising survival data from OVATION 2 Study of treatment of newly diagnosed advanced ovarian cancer to be presented Initiation of Phase ...
Zacks Small Cap Research on MSN1mon
IMNN: Phase 3 Ovarian Cancer Trial to get Underway in Mar 2025…
Phase 3 Ovarian Cancer Trial to Initiate in March 2025 Imunon, Inc. (NASDAQ:IMNN) is continuing preparations to conduct a Phase 3 clinical trial of its lead development compound, IMNN-001 ...
Zacks Small Cap Research on MSN2mon
IMNN: Gearing Up to Initiate Phase 3 Ovarian Cancer Trial in 1Q25…
Imunon, Inc. (NASDAQ:IMNN) is continuing preparations to conduct a Phase 3 clinical trial of its lead development compound, IMNN-001, in patients with advanced ovarian cancer. IMNN-001 is a DNA ...
Yahoo Finance25d
IMNN: Protocol in Place for Phase 3 Trial of IMNN-001 in Ovarian Cancer…
On March 24, 2025, Imunon, Inc. (NASDAQ:IMNN) announced it reached alignment with the U.S. FDA on the protocol for a Phase 3 clinical trial, referred to as OVATION 3, of its lead candidate IMNN ...
Benzinga.com3d
Imunon Stock Short Interest Report | NASDAQ:IMNN | Benzinga
Short interest in Imunon Inc (NASDAQ:IMNN) increased during the last reporting period, rising from 997.88K to 1.20M. This put 8.29% of the company's publicly available shares short. Short interest ...
Nasdaq29d
IMUNON, Inc. Announces Phase 3 Trial for IMNN-001 Following Positive Phase 2 Survival Results in Advanced Ovarian Cancer
IMUNON, Inc. has announced the initiation of a Phase 3 pivotal trial, OVATION 3, for its DNA-mediated immunotherapy candidate, IMNN-001, targeting newly diagnosed advanced ovarian cancer.
Morningstar29d
IMUNON Finalizes Phase 3 Study Design with FDA for IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer
LAWRENCEVILLE, N.J., March 24, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that the U ...
ETF Daily News6d
Imunon (NASDAQ:IMNN) Shares Down 1.9% – What’s Next?
Imunon, Inc. (NASDAQ:IMNN – Get Free Report)’s share price dropped 1.9% during trading on Wednesday .The company traded as low as $0.86 and last traded at $0.86. Approximately 30,040 shares ...
Imunon announces IMNN-001 abstract accepted for oral presentation at 2025 ASCO
IMUNON (IMNN) announced that an abstract highlighting new, highly encouraging, Overall Survival data from the Phase 2 OVATION 2 Study of ...
Morningstar2d
IMUNON Announces IMNN-001 Abstract Accepted for Oral Presentation at 2025 ASCO Annual Meeting
LAWRENCEVILLE, N.J., April 21, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in Phase 3 development of its DNA-mediated immunotherapy, today announced that an ...
manilatimes2d
IMUNON Announces IMNN-001 Abstract Accepted for Oral Presentation at 2025 ASCO Annual Meeting
LAWRENCEVILLE, N.J., April 21, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in Phase 3 development of its DNA-mediated immunotherapy, today announced that an abstract ...